To amend the Federal Food, Drug, and Cosmetic Act to prohibit the marketing of authorized generic drugs.

Summary

Amends the Federal Food, Drug, and Cosmetic Act to prohibit a holder of a new, approved drug application from commencing to manufacture, market, sell, or distribute a generic version of such drug from the time of the receipt of notice from the generic manufacturer that an abbreviated new drug application has been submitted for approval until the expiration or forfeiture of the exclusivity period granted to the generic manufacturer.

This text is taken from the official record. PoliticalRepo does not editorialize.

Timeline

1. 5 February 2007

   Introduced

   Referred to the House Committee on Energy and Commerce.

   Source: IntroReferral

2. 5 February 2007

   Introduced

   Introduced in House

   Source: IntroReferral

3. 5 February 2007

   Introduced

   Introduced in House

   Source: IntroReferral

Votes

No vote records are attached yet.

Versions

• Introduced in House · 5 February 2007 · Official file

Documents

3 official files

• Introduced in House (text)

  Introduced in House · EN · 5 February 2007

  ViewDownloadOpen at official source

• Introduced in House (PDF)

  Introduced in House · EN · 5 February 2007

  ViewDownloadOpen at official source

• Introduced in House

  summary · EN · 5 February 2007

  Open at official source

Sponsors

• Rep. Emerson, Jo Ann [R-MO-8] · R · Sponsor
• Rep. Berry, Marion [D-AR-1] · D · Sponsor
• Rep. Wamp, Zach [R-TN-3] · R · Sponsor
• Rep. Moore, Dennis [D-KS-3] · D · Sponsor
• Rep. Mollohan, Alan B. [D-WV-1] · D · Cosponsor
• Rep. Holden, Tim [D-PA-17] · D · Cosponsor
• Rep. Rahall, Nick J., II [D-WV-4] · D · Cosponsor
• · hsif00 · Standing

Related records

• related to ← Fair Prescription Drug Competition Act